Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system

Molecular Therapy

Volumn 21, Issue 6, 2013, Pages 1195-1203

  Sakurai, Yu ^a   Hatakeyama, Hiroto ^a   Sato, Yusuke ^a   Hyodo, Mamoru ^a   Akita, Hidetaka ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LIPOSOME; MACROGOL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; GENE TARGETING; IN VIVO STUDY; LIPID COMPOSITION; MALE; MOUSE; MULTIFUNCTIONAL ENVELOPE TYPE NANODEVICE; NANODEVICE; NANOENCAPSULATION; NONHUMAN; QUANTITATIVE ANALYSIS; RNA ANALYSIS; RNA INTERFERENCE; TARGET CELL; TOXICITY TESTING; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84878567681     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.57     Document Type: Article

References (35)

1. Burnett, JC and Rossi, JJ (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol 19: 60-71.
2. Castanotto, D and Rossi, JJ (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
3. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
4. Shim, MS and Kwon, YJ (2010). Effcient and targeted delivery of siRNA in vivo. FEBS J 277: 4814-4827.
5. Kogure, K, Akita, H, Yamada, Y and Harashima, H (2008). Multifunctional envelopetype nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev 60: 559-571.
6. Maeda, H, Matsumura, Y and Kato, H (1988). Purifcation and identifcation of [hydroxyprolyl3]bradykinin in ascitic fuid from a patient with gastric cancer. J Biol Chem 263: 16051-16054.
7. Ozpolat, B, Sood, AK and Lopez-Berestein, G (2010). Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 267: 44-53.
8. Hatakeyama, H, Akita, H and Harashima, H (2011). A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63: 152-160.
9. Hatakeyama, H, Akita, H, Ito, E, Hayashi, Y, Oishi, M, Nagasaki, Y et al. (2011). Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specifc cleavable PEG-lipid. Biomaterials 32: 4306-4316.
10. Sakurai, Y, Hatakeyama, H, Sato, Y, Akita, H, Takayama, K, Kobayashi, S et al. (2011). Endosomal escape and the knockdown effciency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32: 5733-5742.
11. Sato, Y, Hatakeyama, H, Sakurai, Y, Hyodo, M, Akita, H and Harashima, H (2012). A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J Control Release 163: 267-276.
12. Landesman, Y, Svrzikapa, N, Cognetta, A 3rd, Zhang, X, Bettencourt, BR, Kuchimanchi, S et al. (2010). In vivo quantifcation of formulated and chemically modifed small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence 1: 16.
13. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identifcation and therapeutic application. Nat Rev Drug Discov 9: 57-67.
14. Kleinman, ME, Yamada, K, Takeda, A, Chandrasekaran, V, Nozaki, M, Baff, JZ et al. (2008). Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597.
15. Lens, SM, Voest, EE and Medema, RH (2010). Shared and separate functions of pololike kinases and aurora kinases in cancer. Nat Rev Cancer 10: 825-841.
16. Patel, HM and Moghimi, SM (1998). Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-The concept of tissue specifcity. Adv Drug Deliv Rev 32: 45-60.
17. Judge, AD, Robbins, M, Tavakoli, I, Levi, J, Hu, L, Fronda, A et al. (2009). Confrming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
18. Robbins, M, Judge, A, Ambegia, E, Choi, C, Yaworski, E, Palmer, L et al. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19: 991-999.
19. Hatakeyama, H, Akita, H, Kogure, K, Oishi, M, Nagasaki, Y, Kihira, Y et al. (2007). Development of a novel systemic gene delivery system for cancer therapy with a tumor-specifc cleavable PEG-lipid. Gene Ther 14: 68-77.
20. Simberg, D, Weisman, S, Talmon, Y and Barenholz, Y (2004). DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 21: 257-317.
21. Moghimi, SM and Hunter, AC (2001). Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm Res 18: 1-8.
22. Joyce, JA and Pollard, JW (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
23. Gao, S, Dagnaes-Hansen, F, Nielsen, EJ, Wengel, J, Besenbacher, F, Howard, KA et al. (2009). The effect of chemical modifcation and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17: 1225-1233.
24. Del Monte, U (2009). Does the cell number 10(9) still really ft one gram of tumor tissue? Cell Cycle 8: 505-506.
25. Holland, JW, Hui, C, Cullis, PR and Madden, TD (1996). Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry 35: 2618-2624.
26. Silvius, JR and Zuckermann, MJ (1993). Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion. Biochemistry 32: 3153-3161.
27. Mok, KW, Lam, AM and Cullis, PR (1999). Stabilized plasmid-lipid particles: factors infuencing plasmid entrapment and transfection properties. Biochim Biophys Acta 1419: 137-150.
28. Heldin, CH, Rubin, K, Pietras, K and Ostman, A (2004). High interstitial fuid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
29. Cabral, H, Matsumoto, Y, Mizuno, K, Chen, Q, Murakami, M, Kimura, M et al. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6: 815-823.
30. Ding, Y, Huang, D, Zhang, Z, Smith, J, Petillo, D, Looyenga, BD et al. (2011). Combined gene expression profling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Cancer Res 71: 5225-5234.
31. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89-102.
32. Wilson, KD, de Jong, SD and Tam, YK (2009). Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic effcacy. Adv Drug Deliv Rev 61: 233-242.
33. Diebold, SS, Kaisho, T, Hemmi, H, Akira, S and Reis e Sousa, C (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
34. Cheng, A, Li, M, Liang, Y, Wang, Y, Wong, L, Chen, C et al. (2009). Stem-loop RT-PCR quantifcation of siRNAs in vitro and in vivo. Oligonucleotides 19: 203-208.
35. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.